My primary area of clinical research is in the treatment and long term care of children with brain and spinal cord tumors, with a specific interest in high grade glioma. Through participation in various consortiums and research groups, I am involved locally in the conduct of clinical trials for patients with newly diagnosed and recurrent tumors. I hope to expand our patients' access to early phase and innovative therapies, including immunotherapy, particularly for difficult to treat tumors.
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology
DOI: 10.1200/JCO.21.02968
2023
A Case of Primary Intracranial Sarcoma, DICER1-Mutant, in a Child with a Germline DICER1 Mutation
Brain Sciences
DOI: 10.3390/brainsci13071040
2023
3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma
Nature Communications
DOI: 10.1038/s41467-023-38044-0
2023
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma
Neuro-oncology
Rosenberg, T. and Yeo, K.K. and Mauguen, A. and Alexandrescu, S. and Prabhu, S.P. and Tsai, J.W. and Malinowski, S. and Joshirao, M. and Parikh, K. and Farouk Sait, S. and Rosenblum, M.K. and Benhamida, J.K. and Michaiel, G. and Tran, H.N. and Dahiya, S. and Kachurak, K. and Friedman, G.K. and Krystal, J.I. and Huang, M.A. and Margol, A.S. and Wright, K.D. and Aguilera, D. and MacDonald, T.J. and Chi, S.N. and Karajannis, M.A.
DOI: 10.1093/neuonc/noac096
2022
Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome
Research Square
DOI: 10.21203/rs.3.rs-1538410/v1
2022
Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome
Pediatric Blood and Cancer
Harris, M.K. and Graham, R.T. and Cappellano, A.M. and Margol, A.S. and Michaiel, G. and Crawford, J.R. and Ioakeim-Ioannidou, M. and Stanek, J.R. and Liu, K.X. and MacDonald, S.M. and Abdelbaki, M.S.
DOI: 10.1002/pbc.29830
2022
Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome
ResearchSquare
Harris, M.K. and Graham, R.T. and Cappellano, A.M. and Margol, A.S. and Michaiel, G. and Crawford, J.R. and Ioakeim-Ioannidou, M. and Stanek, J.R. and Liu, K.X. and MacDonald, S.M. and Abdelbaki, M.S.
DOI: 10.21203/rs.3.rs-1538410
2022
Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature
Journal of Neuro-Oncology
Michaiel, G. and Strother, D. and Gottardo, N. and Bartels, U. and Coltin, H. and Hukin, J. and Wilson, B. and Zelcer, S. and Hansford, J.R. and Hassall, T. and AbdelBaki, M.S. and Cole, K.A. and Hoffman, L. and Smiley, N.P. and Smith, A. and Vinitsky, A. and Vitanza, N.A. and Wright, A. and Yeo, K.K. and Chow, L.M.L. and Vanan, M.I. and Dhall, G. and Bouffet, E. and Lafay-Cousin, L.
DOI: 10.1007/s11060-020-03486-9
2020
Health Practitioners Knowledge, Beliefs, and Attitudes Regarding the Use of Donor Human Milk in Neonatal Intensive Care
Maternal and Pediatric Nutrition
Michael G and Antunes M and Shaik S and Turner J
DOI: 10.4172/2472-1182.1000108
2016
Two promoters with distinct activities in different tissues drive the expression of heparanase in Xenopus
Developmental Dynamics
Bertolesi, G.E. and Su, H.Y. and Michaiel, G. and Dueck, S.M. and Hehr, C.L. and Mcfarlane, S.
DOI: 10.1002/dvdy.22770
2011
Two heparanase splicing variants with distinct properties are necessary in early Xenopus development
Journal of Biological Chemistry
Bertolesi, G.E. and Michaiel, G. and McFarlane, S.
DOI: 10.1074/jbc.M708525200
2008
Carla Willems
A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumours in chicken eggs and analyzing their proteins.
The team, led by researchers from BC Children’s Hospital Research Institute and the University of British Columbia, is the first in Canada to combine these two techniques to identify and test a drug for a young patient's tumour in time for their treatment.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.